AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated